Dilution of Share Value from the Exercise of Stock Acquisition Rights
First written in FY2016. 6 of 14 entries say "Mitigated", first in FY2017. Latest entry: FY2026.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
53 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「As of 31 March 2026, the total number of potential shares attributable to these stock options and share acquisition rights was 1,481,590, equivalent to 10.2% of the 14,519,800 issued shares.」
The potential dilution ratio declined from 10.8% at the end of the previous fiscal year to 10.2%, reducing dilution exposure. - 2026-05-22WorsenedShare Issuance and Disposal
「The shares to be issued upon exercise of the stock options would represent a low 0.6% of the total number of issued shares, and the potential dilution would be limited.」
The stock options for directors would have potential dilution equivalent to 0.6% of total issued shares upon exercise. - FY2025WorsenedAnnual report
「As of 31 March 2025, the total number of potential shares attributable to these stock options and share acquisition rights was 1,569,320, equivalent to 10.8% of the 14,517,100 issued shares.」
The potential dilution ratio rose from 4.4% at the end of the previous fiscal year to 10.8%, expanding dilution exposure including the Tenth Series Share Acquisition Rights. - FY2025-H1WorsenedAnnual report
「The total number of the Company's common shares that would be issued if all of these share acquisition rights were exercised is equivalent to 6.5% of the total number of issued shares.」
On 28 October 2024, share acquisition rights equivalent to 953,700 shares were issued, and the potential dilution if all were exercised was disclosed as 6.5% of the total number of issued shares. This indicates new dilution exposure compared with the potential dilution ratio of 4.4% at the end of the previous fiscal year. - FY2024MitigatedAnnual report
「As of 31 March 2024, the total number of potential shares attributable to these stock options and share acquisition rights was 644,820, equivalent to 4.4% of the 14,516,100 issued shares.」
The potential dilution ratio declined from 7.2% in the previous fiscal year to 4.4%, reducing the dilution exposure disclosed. - FY2023WorsenedAnnual report
「As of 31 March 2023, the total number of potential shares attributable to these stock options and share acquisition rights was 1,018,710, equivalent to 7.2% of the 14,143,600 issued shares.」
The potential dilution ratio rose to 7.2% from 4.6% in the previous fiscal year. Exposure to dilution, including the Ninth Series Share Acquisition Rights, was quantified as of the fiscal year-end. - FY2023-Q3RestatedAnnual report
「The total number of the Company's common shares that would be issued if all of these share acquisition rights were exercised is equivalent to 3.0% of the total number of issued shares.」
The disclosure reconfirms that the potential shares issuable if all of the Ninth Series Share Acquisition Rights were exercised would represent 3.0% of the total number of issued shares. - FY2023-Q2WorsenedAnnual report
「The total number of the Company's common shares that would be issued if all of these share acquisition rights were exercised is equivalent to 3.0% of the total number of issued shares.」
The potential shares issuable if all of the new performance-linked share acquisition rights were exercised were stated to represent 3.0% of the total number of issued shares, indicating new exposure to dilution. - FY2022MitigatedAnnual report
「As of 31 March 2022, the total number of potential shares attributable to these stock options and share acquisition rights was 644,820, equivalent to 4.6% of the 14,098,100 issued shares.」
The potential dilution ratio declined from 5.1% in the previous fiscal year to 4.6%, further reducing exposure to dilution of equity value. - FY2021MitigatedAnnual report
「As of 31 March 2021, the total number of potential shares from these stock options and share acquisition rights was 714,620 shares, equivalent to 5.1% of the total 14,046,200 issued shares.」
The potential dilution ratio declined from 5.9% in the previous fiscal year to 5.1%, further reducing exposure to dilution of equity value. The dilution risk itself continues to be disclosed. - FY2020MitigatedAnnual report
「As of 31 March 2020, the total number of potential shares from these stock options and share acquisition rights was 830,010 shares, equivalent to 5.9% of the total 13,975,500 issued shares.」
The potential share ratio declined from 7.3% in the previous fiscal year to 5.9%, reducing the dilution exposure disclosed by the company. - FY2018RestatedAnnual report
「As of 31 March 2018, the total number of potential shares from these stock options and share acquisition rights was 1,005,080 shares, equivalent to 7.3% of the total 13,837,400 issued shares.」
The potential share ratio was 7.3%, disclosing dilution exposure at the same level as in the previous fiscal year. - FY2017MitigatedAnnual report
「As of 31 March 2017, the total number of potential shares from these stock options and treasury share acquisition rights was 986,700 shares, equivalent to 7.3% of the total 13,601,700 issued shares.」
The potential share ratio declined from 7.8% to 7.3% previously, reducing the dilution exposure disclosed by the company. - FY2016First statedAnnual report
「As of 31 March 2016, the total number of potential shares from these stock options and treasury share acquisition rights was 1,061,200 shares, excluding 3,000 shares attributable to treasury share acquisition rights, equivalent to 7.8% of the total 13,531,700 issued shares.」
The company has granted share acquisition rights as incentives to officers and employees, indicating that the per-share value may be diluted upon exercise.